Bayer files suit against Lupin over plans for generic pill

FRANKFURT Thu Nov 29, 2012 11:25pm IST

A pharmacist counts pills in a pharmacy in Toronto in this January 31, 2008 file photo. REUTERS/Mark Blinch/Files

A pharmacist counts pills in a pharmacy in Toronto in this January 31, 2008 file photo.

Credit: Reuters/Mark Blinch/Files

Related Topics

Stocks

   

FRANKFURT (Reuters) - German drugmaker Bayer(BAYGn.DE) has filed a suit in the United States against Indian generic drug maker Lupin(LUPN.NS), to prevent it from selling a version of Bayer's birth-control pill Natazia there.

In the lawsuit, filed on November 28, Bayer said that Lupin is preparing to bring a copy of the Natazia pill, also called Qlaira, to U.S. markets even though Bayer's U.S. patent on the pill runs through 2026.

The complaint said Bayer would be entitled to an award of damages and treble damages for any commercial sale of the alleged copied product.

Lupin was not immediately available for comment.

Natazia is approved in the U.S. as a contraceptive and for the treatment of heavy menstrual bleeding.

Birth-control is one of the most important businesses for Bayer's pharmaceuticals arm, with contraceptive sales of 1.1 billion euros in 2011.

Bayer Pharma AG v Lupin Ltd. and Lupin Pharmaceuticals Inc. (Case 1:12-cv-01592-UNA) was filed with the U.S. District Court, District of Delaware.

(Reporting by Ludwig Burger and Marilyn Gerlach; Editing by Elaine Hardcastle)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
SamGorawara wrote:
To
Ludwig Burger, Marilyn Gerlach; & Elaine Hardcastle

I wonder why the Lupin comment has not been included in the story inspite of us having responded to your correspondent’s request in less than ten minutes.

Lupin not being availaible for comment is untrue and you publishing this story inpite of us havin send our statment very incorrect reporting.

Shamsher Gorawara
Head, Corporate Communications
Lupin Limited
shamshergorawara@lupinpharma.com
Handy No: +91-9820338555

Nov 29, 2012 4:54am IST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

India-U.S. Talks

India-U.S. Talks

Kerry to woo Modi's India, but quick progress unlikely  Full Article 

Paring Debt

Paring Debt

Jaiprakash to sell hydro plants to Reliance Power  Full Article 

Mideast Conflict

Mideast Conflict

U.N. Security Council calls for humanitarian ceasefire in Gaza  Full Article 

Market Eye

Market Eye

Foreign investors prefer Indian cyclicals, utilities - Macquarie  Full Article 

Debt Investment

Debt Investment

India's FII debt limit hike credit-positive, says Moody's  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage